Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models

Journal of Nuclear Medicine

Volumn 55, Issue 5, 2014, Pages 818-823

  Liu, Zhaofei ^a,b   Sun, Xianlei ^a,b   Liu, Hao ^a,b   Ma, Teng ^a,b   Shi, Jiyun ^a   Jia, Bing ^a,b   Zhao, Huiyun ^a   Wang, Fan ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Angiogenesis; EGFR; Molecular imaging; Therapy response; VEGF

Indexed keywords

BEVACIZUMAB F(AB')2 FRAGMENT; BIOLOGICAL MARKER; DYE; GEFITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE;

ANGIOGENESIS; EGFR; MOLECULAR IMAGING; THERAPY RESPONSE; VEGF;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BIOLOGICAL MARKERS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MODELS, ANIMAL; MOLECULAR IMAGING; NEOPLASM TRANSPLANTATION; NEOPLASMS; OPTICS AND PHOTONICS; QUINAZOLINES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901301880     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.133660     Document Type: Article

References (37)

1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799.
2. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102:37-46.
3. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitorsimpact on future treatment strategies. Nat Rev Clin Oncol. 2010;7:493-507.
4. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17:259-269.
5. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002;62:2554-2560.
6. Bozec A, Formento P, Ciccolini J, et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther. 2005;4:1962-1971.
7. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803.
8. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5:203-220.
9. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-2008.
10. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2002;62:4300-4306.
11. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66:3197-3204.
12. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
13. Fu Y, Hou Y, Fu C, et al. A novel mechanism of gamma/delta T-lymphocyte and endothelial activation by shear stress: the role of ecto-ATP synthase beta chain. Circ Res. 2011;108:410-417.
14. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004;64:8009-8014.
15. Liu Z, Jia B, Zhao H, Chen X, Wang F. Specific targeting of human integrin alphavbeta3 with 111In-labeled Abegrin in nude mouse models. Mol Imaging Biol. 2011;13:112-120.
16. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319.
17. Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer. 2008;122:2310-2314.
18. Chang AJ, Sohn R, Lu ZH, Arbeit JM, Lapi SE. Detection of rapalog-mediated therapeutic response in renal cancer xenografts using 64Cu-bevacizumab immunoPET. PLoS ONE. 2013;8:e58949.
19. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted 86Y-CHX-A$-DTPA- bevacizumab. Int J Cancer. 2011;128:920-926.
20. Nagengast WB, Hooge MN, van Straten EM, et al. VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer. 2011;47:1595-1602.
21. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191-197.
22. Zhang Y, Hong H, Orbay H, et al. PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging. 2013;40:759-767.
23. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol. 2005;25:1-18.
24. Orlova A,Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 2009;50:417-425.
25. Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med. 2009;50(suppl 1):106S-121S.
26. Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med. 2011;52:140-146.
27. Janjigian YY, Viola-Villegas N, Holland JP, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013;54:936-943.
28. Helfrich BA, Raben D,Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006;12:7117-7125.
29. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer. 2004;91:208-212.
30. Herbst RS, Fukuoka M, Baselga J. Gefitinib: a novel targeted approach to treating cancer. Nat Rev Cancer. 2004;4:956-965.
31. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
32. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
33. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
34. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. JClin Oncol. 2005;23:5007-5018.
35. Hirata A, Uehara H, Izumi K, Naito S, Kuwano M, Ono M. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci. 2004;95:614-618.
36. Kosaka N, Ogawa M, Choyke PL, Kobayashi H. Clinical implications of nearinfrared fluorescence imaging in cancer. Future Oncol. 2009;5:1501-1511.
37. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23:313-320.